Pascal Biosciences

Pascal Biosciences is a biopharmaceutical company focused on advancing innovative approaches to cancer treatment, including cannabinoid-based therapies and targeted therapies. The company's leading cannabinoid portfolio includes a small molecule therapeutic agent, ST-403, and an immune-stimulating molecule. ST-403 is currently in clinical trials for the treatment of glioblastoma. Additionally, Pascal Biosciences is developing a B-cell antibody for acute lymphoblastic leukemia and an antibody targeting calcium channels expressed in the immune system.